ADT such as long-acting GnRH agonists (goserelin, histrelin, leuprolide, and triptorelin) or GnRH antagonists (degarelix), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone are the first line therapy for patients with metastatic disease [147]. Here, GNRH1 is linked to metastatic neoplasm.